Skymap Pharmaceuticals Private Limited, a active private limited company, was established on 24 June 2006 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24233DL2006PTC150088. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹6.50 Cr and a paid-up capital of ₹5.00 M.
Formerly known as Skymap Pharma Private Limited, Gsk Pharmaceuticals Private Limited.. It upholds a compliant status. Employing 314 professional, Its leadership includes Vinod Kumar Gupta (Director), Sanjay Gupta (Director), Manish Garg (Director). Past directors included Kishori Lal Gupta, Manish Garg. It holds ₹422.75 Cr open charges and ₹292.84 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 302, Narmada Block-5 Pocket D-6, Vasant Kunj, New Delhi, Delhi, 110070.
U24233DL2006PTC150088
150088
24 June 2006
₹6.50 Cr
₹5.00 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Skymap Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vinod Kumar Gupta | Director | 12 Oct 2017 | Current |
| Sanjay Gupta | Director | 24 Jun 2006 | Current |
| Manish Garg | Director | 29 Sep 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 09 Oct 2016 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Skymap Pharmaceuticals Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 13.68% increase. The company also saw a substantial improvement in profitability, with a 2341.28% increase in profit. The company's net worth Soared by an impressive increase of 29.24%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Skymap Pharmaceuticals had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹4,227,500,000.00
₹2,928,350,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Mar 2020 | Hdfc Bank Limited | ₹9.50 M | Open |
| 02 Aug 2018 | Hdfc Bank Limited | ₹344.52 Cr | Open |
| 02 Jul 2015 | Hdfc Bank Limited | ₹77.29 Cr | Open |
| 23 Jul 2019 | Citi Bank N.A. | ₹8.00 Cr | Satisfied |
| 26 May 2017 | Hdfc Bank Limited | ₹284.84 Cr | Satisfied |
Explore comprehensive loan charge details -
Skymap Pharmaceuticals has a workforce of 314 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Skymap Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skymap Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge with Hdfc Bank Limited of Rs. 344.52 Cr registered on 02 Aug 2018 with Charge ID 100206277 was modified on 25 Apr 2025. was completed.
Progress on A charge with Hdfc Bank Limited of Rs. 77.29 Cr registered on 02 Jul 2015 with Charge ID 10587853 was modified on 25 Apr 2025. was documented.
The activity Skymap Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Skymap Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was recorded as a recent event.
A charge registered on 26 May 2017 via Charge ID 100114747 with Hdfc Bank Limited was fully satisfied on 07 Mar 2024. was recorded as a recent event.
A charge with Hdfc Bank Limited of Rs. 284.84 Cr registered on 26 May 2017 with Charge ID 100114747 was modified on 17 Apr 2023. was recorded as a recent event.
The CIN of Skymap Pharmaceuticals Private Limited is U24233DL2006PTC150088.
Skymap Pharmaceuticals Private Limited is headquartered at 302, Narmada Block-5 Pocket D-6, Vasant Kunj, New Delhi, Delhi, 110070.
Skymap Pharmaceuticals Private Limited was incorporated on 24 June 2006.
The current directors of Skymap Pharmaceuticals Private Limited are
The primary industry of Skymap Pharmaceuticals Private Limited is Manufacturing.
Skymap Pharmaceuticals Private Limited is unlisted.
The authorized capital of Skymap Pharmaceuticals Private Limited is ₹6.50 Cr, and the paid-up capital is ₹5.00 M.
The compliance status of Skymap Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX